TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD
Clinical and Molecular Hepatology · 01.10.2024 · 30 (4) · 863-882
DOI: 10.3350/cmh.2024.0268 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.10.2024. Verfasst von Baokai Sun und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Qingdao Municipal Hospital, Qingdao University, Qingdao, China. Hauptthemen laut MEDLINE: Membrane Proteins, Lipase, Fatty Acids, Unsaturated, Diet, High-Fat. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Natural Science Foundation of China, Taishan Scholar Foundation of Shandong Province.
Abstract (Originalsprache)
Backgrounds/Aims: Transmembrane 6 superfamily member 2 (TM6SF2) E167K variant is closely associated with the occurrence and development of metabolic dysfunction-associated steatotic liver disease (MASLD). However, the role and mechanism of TM6SF2 E167K variant during MASLD progression are not yet fully understood.
Methods
The Tm6sf2167K knock-in (KI) mice were subjected to high-fat diet (HFD). Hepatic lipid levels of Tm6sf2167K KI mice were detected by lipidomics analysis. Thin-layer chromatography (TLC) was used to measure the newly synthesized triglyceride (TG) and phosphatidylcholine (PC).
Results
The TM6SF2 E167K variant significantly aggravated hepatic steatosis and injury in HFD-induced mice. Decreased polyunsaturated PC level and increased polyunsaturated TG level were found in liver tissue of HFD-induced Tm6sf2167K KI mice. Mechanistic studies demonstrated that the TM6SF2 E167K variant increased the interaction between TM6SF2 and PNPLA3, and impaired PNPLA3-mediated transfer of polyunsaturated fatty acids (PUFAs) from TG to PC. The TM6SF2 E167K variant increased the level of fatty acid-induced malondialdehyde and reactive oxygen species, and decreased fatty acid-downregulated cell membrane fluidity. Additionally, the TM6SF2 E167K variant decreased the level of hepatic PC containing C18:3, and dietary supplementation of PC containing C18:3 significantly attenuated the TM6SF2 E167K-induced hepatic steatosis and injury in HFD-fed mice.
Conclusions
The TM6SF2 E167K variant could promote its interaction with PNPLA3 and inhibit PNPLA3-mediated transfer of PUFAs from TG to PC, resulting in the hepatic steatosis and injury during MASLD progression. PC containing C18:3 could act as a potential therapeutic supplement for MASLD patients carrying the TM6SF2 E167K variant.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.
- Clinical Research Center, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.
- Central Laboratories, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.
Förderung
- National Natural Science Foundation of China
- Taishan Scholar Foundation of Shandong Province
Zitieren
APA
Sun, B., Ding, X., Tan, J., Zhang, J., Chu, X., Zhang, S., Liu, S., Zhao, Z., Xuan, S., Xin, Y., & Zhuang, L. (2024). TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD. Clinical and Molecular Hepatology, 30(4), 863-882. https://doi.org/10.3350/cmh.2024.0268
Vancouver
Sun B, Ding X, Tan J, Zhang J, Chu X, Zhang S, et al. TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD. Clinical and Molecular Hepatology. 2024;30(4):863-882. doi:10.3350/cmh.2024.0268
BibTeX
@article{Sun2024,
author = {Sun, Baokai and Ding, Xiaoqian and Tan, Jie and Zhang, Jie and Chu, Xueru and Zhang, Shuimi and Liu, Shousheng and Zhao, Zhenzhen and Xuan, Shiying and Xin, Yongning and Zhuang, Likun},
title = {TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD},
journal = {Clinical and Molecular Hepatology},
year = {2024},
volume = {30},
number = {4},
pages = {863--882},
doi = {10.3350/cmh.2024.0268}
}
EUVIMED